LGND
LIGAND PHARMACEUTICALS INC
$237.75
+0.32%
$4.9B
No data for this timeframe.
Vol
Market Cap$4.9B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders6 funds
Inst. Value$620.8M
Inst. Activity1 buys / 0 sells
Insider Activity0B / 11S
Insider Net $-$2.2M
SEC Reports2
Press Releases1
Congressional2 trades
Recent Activity
Jun 5, 2026
Insider
Gray Nancy Ryan sold 836 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
LAMATTINA JOHN L sold 2,938 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
LAMATTINA JOHN L sold 836 shares
Director @ $0.00 ($0.00)
May 15, 2026
SEC
Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligan
CLUSTER — Impact 3/10
Feb 26, 2026
SEC
Ligand Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by a 48% increase in
8-K — Impact 8/10
Inst.
FMR LLC — ADD
579,155 shares ($109.5M)
Inst.
FMR LLC — DOUBLED
457,231 shares ($81.0M)
May 27, 2026
other
Ligand to Participate in June Investor Conferences
Ligand to Participate in June Investor Conferences
Price Targets
$277.60
+14.1% upside
Buy
Current $243.28
Low $247.00
Median $278.50
High $330.00
10 analysts
$247.00
$330.00
Analyst Ratings
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 15, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.99 ▼ -2.8% | $1.71 — $2.15 | 24% YoY | 8 |
| Next Q | $2.51 ▼ -5.3% | $2.33 — $2.66 | -19% YoY | 7 |
| Current FY | $9.10 ▼ -1.6% | $8.79 — $9.67 | 12% YoY | 7 |
| Next FY | $11.32 ▼ -4.2% | $10.46 — $12.58 | 24% YoY | 6 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligan
May 15, 2026
BULLISH
Press
8/10
Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSG
Apr 14, 2026
BULLISH
8-K
8/10
Ligand Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by a 48% increase in
Feb 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $392.1M | — |
| FMR LLC | $109.5M | ADD |
| MORGAN STANLEY | $36.6M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $34.8M | NEW |
| WELLS FARGO & COMPANY/MN | $25.1M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Gray Nancy | A | $0.00 |
| Jun 5, 2026 | LAMATTINA JOHN | A | $0.00 |
| Jun 5, 2026 | LAMATTINA JOHN | A | $0.00 |
| Jun 5, 2026 | Sabba Stephen | A | $0.00 |
| Jun 5, 2026 | Sabba Stephen | A | $0.00 |
Congressional Trades
1 members: 2 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
6 institutional holders with $620.8M total value (3,283,538 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,073,892 | $392.1M | 63.2% | — |
| 2 | FMR LLC | 579,155 | $109.5M | 17.6% | ADD +26.7% |
| 3 | MORGAN STANLEY | 193,402 | $36.6M | 5.9% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 184,284 | $34.8M | 5.6% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 132,636 | $25.1M | 4.0% | DOUBLED +769.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 120,169 | $22.7M | 3.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 457,231 | 579,155 | +26.7% | $109.5M | 2025-Q4 |
| FMR LLC | DOUBLED | 26,223 | 457,231 | +1643.6% | $81.0M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 13,241 | 115,177 | +769.9% | $20.4M | 2025-Q3 |
| UBS Group AG | DOUBLED | 33,510 | 111,986 | +234.2% | $19.8M | 2025-Q3 |
| NORGES BANK | EXIT | 14,073 | 0 | -100.0% | $0.00 | 2025-Q3 |
| Tweedy, Browne Co LLC | EXIT | 3,140 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 14,073 | — | $1.6M | 2025-Q2 |
| Tweedy, Browne Co LLC | NEW | — | 3,140 | — | $357.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 2,800 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | ADD | 18,831 | 24,933 | +32.4% | $2.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 17,500 | 7,300 | -58.3% | $767.5K | 2025-Q1 |
| NORGES BANK | EXIT | 46,290 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 11,497 | 27,105 | +135.8% | $2.9M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 41,114 | 17,500 | -57.4% | $1.9M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 8,650 | 11,220 | +29.7% | $1.2M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 3,000 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 163,924 | — | $16.4M | 2024-Q3 |
9 unique insiders with 11 transactions. Net insider value: -$2.2M ($0.00 bought, $2.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Gray Nancy Ryan | Director | A | 836 | $0.00 | $0.00 |
| Jun 5, 2026 | LAMATTINA JOHN L | Director | A | 2,938 | $0.00 | $0.00 |
| Jun 5, 2026 | LAMATTINA JOHN L | Director | A | 836 | $0.00 | $0.00 |
| Jun 5, 2026 | Sabba Stephen L | Director | A | 2,938 | $0.00 | $0.00 |
| Jun 5, 2026 | Sabba Stephen L | Director | A | 836 | $0.00 | $0.00 |
| Jun 5, 2026 | Zimmermann Martine | Director | A | 2,938 | $0.00 | $0.00 |
| Jun 5, 2026 | Zimmermann Martine | Director | F | 182 | $237.00 | $43.1K |
| Jun 5, 2026 | Zimmermann Martine | Director | A | 836 | $0.00 | $0.00 |
| Jun 5, 2026 | KOZARICH JOHN W | Director | A | 2,938 | $0.00 | $0.00 |
| Jun 5, 2026 | KOZARICH JOHN W | Director | A | 836 | $0.00 | $0.00 |
| Jun 5, 2026 | Haas Jason | Director | A | 2,938 | $0.00 | $0.00 |
| Jun 5, 2026 | Haas Jason | Director | A | 836 | $0.00 | $0.00 |
| Jun 5, 2026 | Gray Nancy Ryan | Director | A | 2,938 | $0.00 | $0.00 |
| Jun 1, 2026 | Reardon Andrew | CLO & Secretary | SELL | 491 | $223.95 | $110.0K |
| Jun 1, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $52.27 | $261.4K |
| Jun 1, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $0.00 | $0.00 |
| May 27, 2026 | Espinoza Octavio | Chief Financial Officer | M | 764 | $63.62 | $48.6K |
| May 27, 2026 | Espinoza Octavio | Chief Financial Officer | M | 972 | $0.00 | $0.00 |
| May 13, 2026 | KOZARICH JOHN W | Director | M | 1,575 | $69.51 | $109.5K |
| May 13, 2026 | KOZARICH JOHN W | Director | SELL | 1,575 | $223.50 | $352.0K |
| May 13, 2026 | KOZARICH JOHN W | Director | M | 1,575 | $0.00 | $0.00 |
| May 12, 2026 | KOZARICH JOHN W | Director | M | 459 | $69.51 | $31.9K |
| May 12, 2026 | KOZARICH JOHN W | Director | SELL | 459 | $224.00 | $102.8K |
| May 12, 2026 | KOZARICH JOHN W | Director | M | 459 | $0.00 | $0.00 |
| May 1, 2026 | KOZARICH JOHN W | Director | SELL | 80 | $227.37 | $18.2K |
| May 1, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $52.27 | $261.4K |
| May 1, 2026 | Reardon Andrew | CLO & Secretary | SELL | 600 | $227.45 | $136.5K |
| May 1, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $52.27 | $261.4K |
| Apr 1, 2026 | Reardon Andrew | CLO & Secretary | SELL | 460 | $198.85 | $91.5K |
| Apr 1, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $0.00 | $0.00 |
| Apr 1, 2026 | KOZARICH JOHN W | Director | SELL | 146 | $199.97 | $29.2K |
| Mar 23, 2026 | Sabba Stephen L | Director | SELL | 1,000 | $207.87 | $207.9K |
| Mar 11, 2026 | Espinoza Octavio | Chief Financial Officer | M | 2,405 | $92.65 | $222.8K |
| Mar 11, 2026 | Espinoza Octavio | Chief Financial Officer | M | 2,405 | $0.00 | $0.00 |
| Mar 11, 2026 | Espinoza Octavio | Chief Financial Officer | SELL | 3,057 | $225.00 | $687.8K |
| Mar 6, 2026 | LAMATTINA JOHN L | Director | M | 2,161 | $114.15 | $246.7K |
| Mar 6, 2026 | LAMATTINA JOHN L | Director | SELL | 2,161 | $200.76 | $433.8K |
| Mar 6, 2026 | LAMATTINA JOHN L | Director | M | 2,161 | $0.00 | $0.00 |
| Mar 4, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $52.27 | $261.4K |
| Mar 4, 2026 | Espinoza Octavio | Chief Financial Officer | M | 1,607 | $58.49 | $94.0K |
| Mar 4, 2026 | Espinoza Octavio | Chief Financial Officer | M | 1,607 | $0.00 | $0.00 |
| Mar 4, 2026 | Reardon Andrew | CLO & Secretary | M | 5,000 | $0.00 | $0.00 |
| Mar 3, 2026 | Sabba Stephen L | Director | M | 2,034 | $69.51 | $141.4K |
| Mar 3, 2026 | Sabba Stephen L | Director | M | 2,034 | $0.00 | $0.00 |
| Mar 2, 2026 | KOZARICH JOHN W | Director | SELL | 47 | $197.14 | $9.3K |
| Mar 2, 2026 | Reardon Andrew | CLO & Secretary | A | 4,513 | $0.00 | $0.00 |
| Mar 2, 2026 | Reardon Andrew | CLO & Secretary | A | 21,525 | $0.00 | $0.00 |
| Mar 2, 2026 | Davis Todd C | Chief Executive Officer | A | 10,495 | $0.00 | $0.00 |
| Mar 2, 2026 | Davis Todd C | Chief Executive Officer | A | 50,058 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$277.60 mean target
+14.1% upside
Buy (1.22)
$247.00 Low
$330.00 High
| Metric | Value |
|---|---|
| Current Price | $243.28 |
| Target Low | $247.00 |
| Target Mean | $277.60 |
| Target Median | $278.50 |
| Target High | $330.00 |
| # Analysts | 10 |
| Recommendation | Buy (1.22) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.99 | $1.71 | $2.15 | 24.4% | -2.8% | 3↑ 1↓ | $0.1B | 33.0% | 8 |
| Next Q 2026-09-30 |
$2.51 | $2.33 | $2.66 | -18.8% | -5.3% | 2↑ 1↓ | $0.1B | -31.6% | 7 |
| Current FY 2026-12-31 |
$9.10 | $8.79 | $9.67 | 11.9% | -1.6% | 2↑ 2↓ | $0.3B | 7.3% | 7 |
| Next FY 2027-12-31 |
$11.32 | $10.46 | $12.58 | 24.3% | -4.2% | 1↑ 3↓ | $0.4B | 28.8% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.990 | |
| 7d ago | $2.006 | -0.016 |
| 30d ago | $2.048 | -0.058 |
| 60d ago | $2.021 | -0.031 |
| 90d ago | $1.984 | +0.006 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 15, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | B of A Securities | INITIATE | — | Buy |
| Feb 27, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 2 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Ligand Pharmaceuticals Inc | Feb 16, 2026 (33d) |
| Jan 5, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Ligand Pharmaceuticals Inc | Feb 16, 2026 (43d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
other
Ligand to Participate in June Investor Conferences
Ligand to Participate in June Investor Conferences
May 7, 2026
earnings
Ligand Reports First Quarter 2026 Financial Results
Ligand Reports First Quarter 2026 Financial Results
May 7, 2026
earnings_calendar
LGND Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
other
Ligand to Participate in May Investor Conferences
Ligand to Participate in May Investor Conferences
Apr 29, 2026
fda_pdufa
PDUFA: LGND — Tzield in delay the onset of stage 3 type 1 diabetes (T1D) in patients as young as one year old with stage 2 T1D — 2026-04-29
FDA target action date 2026-04-29 for LGND (LIGAND PHARMACEUTICALS INC). Drug: Tzield. Indication: delay the onset of stage 3 type 1 diabetes (T1D) in
Apr 28, 2026
short_interest
FTD: LGND — 7,675 shares ($1.9M) failed to deliver
Settlement: 20260428, Price: $241.79, FTD Value: $1,855,738.25, LIGAND PHARMACEUTICALS INC COM
Apr 14, 2026
fda
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Apr 13, 2026
fda_pdufa
PDUFA: LGND — FILSPARI in focal segmental glomerulosclerosis (FSGS) — 2026-04-13
FDA target action date 2026-04-13 for LGND (LIGAND PHARMACEUTICALS INC). Drug: FILSPARI. Indication: focal segmental glomerulosclerosis (FSGS). FDA ex
Mar 26, 2026
other
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Mar 5, 2026
short_interest
FTD: LGND — 9,257 shares ($1.9M) failed to deliver
Settlement: 20260305, Price: $208.95, FTD Value: $1,934,250.15, LIGAND PHARMACEUTICALS INC COM
Mar 4, 2026
other
Ligand to Participate in March Investor Conferences
Ligand to Participate in March Investor Conferences
Feb 26, 2026
earnings_calendar
LGND Q4 2025 Earnings Before Market Open — 2026-02-26